Using gastrointestinal cancer cells and a series of high-throughput screening (HTS) tests, scientists from Cannabics Pharmaceuticals Inc. revealed that two non-intoxicating cannabinoids cannabigerol (CBG) and cannabichromene (CBC) both exhibit anti-tumour properties.
Both CBG and CBC are naturally occurring cannabinoids found exclusively in the cannabis plant called phytocannabinoids, although both are usually found in much smaller concentrations than the two more commonly known phytocannabinoids, difference between tetrahydrocannabinol (THC) and cannabidiol (CBD).
The results of the experiment highlight a correlation between the presence of these cannabinoids and an increased rate of necrosis in cancer cells, which ultimately causes the cells to die. It is believed that because both CBG and CBC are neutral molecules (as opposed to being polarised or acidic), they can penetrate into a cancer cell’s membrane, increasing their anti-tumour potential.
Dr Ballan, co-founder of Cannabics Pharmaceuticals Inc. said, “We are intrigued by the results we have obtained in the lab and our aim is to consider placing an emphasis on this organ system and to further explore the differential anti-tumour properties of cannabinoids. We believe that these preliminary results vindicate our vision; which is to bring personalisation into cannabinoid-based cancer treatments.”
Earlier in February 2020 and following this discovery, Cannabics Pharmaceuticals Inc. announced that they have signed a ‘Memorandum of Understanding’ with RCK Medical Cannabis in Israel to develop specific strains of medical cannabis aimed at treating gastrointestinal cancers.